University of Minnesota
https://twin-cities.umn.edu/
612-625-5000
Milestone
6.2.a

Lessons from COVID-19 R&D

Completed
High priority

Distill lessons learned for influenza vaccines from experience with COVID-19 vaccine R&D, including clinical research and study designs, manufacturing, distribution, advocacy, financing, and global collaboration.

Progress Highlights

Ballou 2022, NASEM 2022: the National Academy of Medicine (collaborator: US CDC/PIVI) convened a workshop focused on lessons learned from COVID-19 to inform and advance pandemic and seasonal influenza vaccine preparedness efforts and subsequent response. 

See discussion paper

See workshop proceedings


Krammer 2023 reviewed COVID-19 vaccine development during the pandemic and highlighted scientific, technological, and policy issues that need to be addressed for pandemic preparedness, including the need to provide sufficient R&D funding and to counteract vaccine hesitancy, misinformation, and anti-vax conspiracy movements. 

See research


Palache 2023 (IFPMA) summarized lessons learned for vaccine manufacturing during a pandemic (e.g., regarding pathogen surveillance and data sharing, equitable distribution, and pharmaceutical partnerships to accelerate R&D and manufacturing).

See research


Arinaminpathy 2022 summarized lessons learned for influenza vaccine R&D from the COVID-19 pandemic in the topic areas of epidemiological implications, economic implications, global production capacity, and roles for donors and policy-makers. 

See research


Johnson 2022 (BARDA) summarized lessons learned from the development of COVID-19 vaccines, including gaps and challenges that must be addressed to prepare for future outbreaks caused by pandemic viruses. 

See research